Your browser doesn't support javascript.

Portal de Pesquisa da BVS

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
XML
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study.

Brizot, Maria L; Hernandez, Wagner; Liao, Adolfo W; Bittar, Roberto E; Francisco, Rossana P V; Krebs, Vera L J; Zugaib, Marcelo.
Am J Obstet Gynecol ; 213(1): 82.e1-82.e9, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25731690

OBJECTIVE:

The purpose of this study was to investigate the use of vaginal progesterone for the prevention of preterm delivery in twin pregnancies.

STUDY DESIGN:

We conducted a prospective, randomized, double-blind, placebo-controlled trial that involved 390 naturally conceived twin pregnancies among mothers with no history of preterm delivery who were receiving antenatal care at a single center. Women with twin pregnancies between 18 and 21 weeks and 6 days' gestation were assigned randomly to daily vaginal progesterone (200 mg) or placebo ovules until 34 weeks and 6 days' gestation. The primary outcome was the difference in mean gestational age at delivery; the secondary outcomes were the rate of spontaneous delivery at <34 weeks' gestation and the rate of neonatal composite morbidity and mortality in the treatment and nontreatment groups.

RESULTS:

The baseline characteristics were similar in both groups. The final analysis included 189 women in the progesterone group and 191 in the placebo group. No difference (P = .095) in the mean gestational age at delivery was observed between progesterone (35.08 ± 3.19 [SD]) and placebo groups (35.55 ± 2.85). The incidence of spontaneous delivery at <34 weeks' gestation was 18.5% in the progesterone group and 14.6% in the placebo group (odds ratio, 1.32; 95% confidence interval, 0.24-2.37). No difference in the composite neonatal morbidity and mortality was observed between the progesterone (15.5%) and placebo (15.9%) groups (odds ratio, 1.01; 95% confidence interval, 0.58-1.75).

CONCLUSION:

In nonselected twin pregnancies, vaginal progesterone administration does not prevent preterm delivery and does not reduce neonatal morbidity and death.